Clinical Trial Update: Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study evaluating Xaluritamig in combination with androgen receptor pathway inhibitors in metastatic hormone-sensi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer

Drugs mentioned

• Xaluritamig (Xaluritamig)

Snippet

Sponsor: Amgen | Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 1 | Status: RECRUITING